Bristol Myers Squibb Announces OPDIVO ® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

This material is intended to notify the press release issued on June 1 (local time) by Bristol Myers Squibb, our license partner for OPDIVO. Please click https://www.bms.com/media/press-releases.html for the original press release.

The release as fetched from its publisher. ono-pharma.com ↗